Printer Friendly

GenVec Inc publishes research paper on improved vaccine vectors.

M2 EQUITYBITES-April 9, 2012-GenVec Inc publishes research paper on improved vaccine vectors(C)2012 M2 COMMUNICATIONS http://www.m2.com

Biopharmaceutical company GenVec Inc (NASDAQ:GNVC) reported on Friday the online publication of a research paper on its new improved vaccine vectors in PloS ONE, which can be accessed at http://dx.plos.org/10.1371/journal.pone.0033920.

The company said that the vectors circumvent neutralizing antibodies in order to generate the desired immunologic response.

According to the company, the article titled "Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses" is an example of GenVec's proprietary vaccine technology.

Douglas E. Brough, Ph.D., the company's vice president of Research, added the new approach alters key elements of the vector so that a good vaccine response is generated even if an individual was previously exposed to an adenovirus.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2012 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Apr 9, 2012
Words:157
Previous Article:Boston Therapeutics Inc commences SUGARDOWN publicity campaign to target diabetes market.
Next Article:Verizon Wireless expands and enhances 4G LTE network coverage in Vernon, Connecticut.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters